BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
Cybin: Regulatory Tailwinds Unlock Asymmetric Upside (Rating Upgrade)
FTSE 100 Live: London stocks slide as aerospace and defence sector falls
Psychedelics stocks rise after Trump order expands research, access pathways
Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder Prepared Remarks Transcript
Cybin (OTCMKTS:CYBN) Stock Price Up 1.2% – Here’s Why
Cybin Initiates At-The-Market Equity Program of up to US$100 Million
Cybin (NYSEAMERICAN:CYBN) Stock Price Up 4.4% – Should You Buy?
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq
Cybin (NYSEAMERICAN:CYBN) Trading Down 8.2% – Here’s Why
Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript
Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
Cybin to Participate in the Jefferies Global Healthcare Conference in London
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025
Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Cybin to Participate at the 2025 Milken Institute Future of Health Summit
Cybin Announces Closing of $175 Million Registered Direct Offering
Cybin Announces $175 Million Registered Direct Offering
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm
Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Cybin Announces Results of Annual Meeting of Shareholders
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference
Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High?
Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
3 High-Risk, High-Reward Stocks With Explosive Upside
REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights
Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics